small cap biotech 2026
GRI Bio Won Orphan Drug Status the Same Day MAIA Opened a Third Cancer Trial Site
GRI Bio’s stock is down 94% over the past year. On June 18, the FDA handed it seven years of potential market exclusivity. The same day, across the industry, a different small-cap was quietly opening its third US trial site for a lung cancer drug nobody outside biotech circles has heard of. Regulatory wins and…
Pancreatic Cancer Trial Ahead of Schedule, Gastric Cancer Fast Track Win
A drug called givastomig produced a 77% response rate in gastric cancer. The stock trades 71% below its 52-week high. Sometimes the data and the price tell two different stories. AIM ImmunoTech Doses Final Patient in Phase 2 Pancreatic Cancer Trial Ahead of Schedule AIM ImmunoTech (NYSE American: AIM) had a busy stretch in the…
Pancreatic Cancer Phase 3 Starts, Ovarian Cancer Phase 1 Wins
51,000 Americans will be diagnosed with pancreatic cancer this year. Roughly 45,000 will die from it. The five-year survival rate has not meaningfully changed since 2000. On June 11, a company called Immuneering dosed its first Phase 3 patient. Immuneering Corporation Doses First Patient in Phase 3 MAPKeeper 301 Pancreatic Cancer Trial Immuneering Corporation (Nasdaq:…
Three Cancer Drug Programs Advanced This Week and Nobody Noticed
MAIA Biotechnology got FDA clearance to open US enrollment for its Phase 2 lung cancer trial on June 3. ADC Therapeutics released Phase 3 data confirming ZYNLONTA extends progression-free survival in lymphoma the same day. Verastem got an FDA Fast Track for its KRAS G12D inhibitor in lung cancer the day after. Three different companies,…
Ivonescimab posted a 34% survival benefit at ASCO — the FDA decides in November
ASCO week closed with one result that changed the conversation about lung cancer. Ivonescimab cut the risk of death by 34% in squamous NSCLC. The data landed in a Plenary Session. It was published simultaneously in The Lancet. It was the first time in the 61-year history of ASCO that a China-originated drug has been…
